Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Contact for Program Information
CONTACT
Lead
Daiichi Sankyo
A patient enrolled in the MAP can continue treatment until any of the following occurs, whichever comes first: * Disease progression. * Unacceptable toxicity. * The benefit-risk no longer favors the individual. * Valemetostat tosylate becomes commercially available in the US or other treatment options become available. * Withdrawal of consent to continue treatment. * Pregnancy. * Physician discretion. * Death.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
